Skip to main content

Day: June 19, 2020

Nasdaq Pledges Continued Commitment to Diversity and Inclusion

Makes Donations to the Equal Justice Initiative and NAACPDebuts ‘Amplifying Black Voices’ Artist Series on Nasdaq MarketSite TowerLaunches Bell Ceremony Series to Acknowledge Frontline HeroesNEW YORK, June 19, 2020 (GLOBE NEWSWIRE) — Nasdaq, Inc. announced today additional steps in its continued commitment to diversity and inclusion. Actions from the company will include cash donations to organizations fighting racial injustice and increased investment in the company’s internal programs, including professional advancement and talent acquisition, to foster a diverse and inclusive corporate culture.“The on-going health crisis and recent events we have all witnessed have magnified the injustices disproportionally impacting Black communities,” said Adena Friedman, President and Chief Executive Officer, Nasdaq. “There has been an outpouring...

Continue reading

Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis

Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitisDupixent included in China’s list of overseas approved drugs that meet urgent clinical needDupixent is approved in 60 countries for adults with moderate-to-severe atopic dermatitis, one of the diseases driven by type 2 inflammationPARIS and TARRYTOWN, NY – June 19, 2020 – The National Medical Products Administration (NMPA) in China has approved Dupixent® (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NMPA identified Dupixent as an overseas medicine considered urgently needed in clinical practice, leading to an expedited review and approval process.“The limited treatment options in China for...

Continue reading

Dupixent® (dupilumab) approuvé en Chine pour le traitement de la dermatite atopique modérée à sévère de l’adulte

Dupixent® (dupilumab) approuvé en Chine pour le traitement de la dermatite atopique modérée à sévère de l’adulteInscription de Dupixent sur la liste des médicaments étrangers en Chine répondant à un besoin clinique urgentDupixent est approuvé dans 60 pays pour le traitement de la dermatite atopique modérée à sévère de l’adulte – une des maladies médiées par une inflammation de type 2  PARIS et TARRYTOWN (New York) – Le 19 juin 2020 – L’Agence nationale des médicaments (National Medical Products Administration, NMPA) de Chine a approuvé Dupixent® (dupilumab) pour le traitement de la dermatite atopique modérée à sévère de l’adulte non contrôlé par des traitements topiques soumis à prescription médicale ou auquel ces traitements sont déconseillés. La NMPA a identifié Dupixent comme un médicament étranger dont la Chine a un besoin urgent...

Continue reading

Pixium Vision selected to participate in the Next French Healthcare program organized by Business France and BPI France, bolstering presence in the US

Pixium Vision selected to participate in the Next French Healthcare program organized by Business France and Bpifrance, bolstering presence in the USParis, 19 June 2020 – 07.30 am CET– Pixium Vision (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announces it is one of the 13 laureates selected among the most innovative French lifescience companies to take part in a US investor roadshow in October 2020, organized by Business France and Bpifrance.Pixium Vision will update investors on its plans for the bionic vision Prima System and increase awareness in the US of its exciting development and commercial plans. Recent 18-month data have shown the Prima System is able to combine natural residual...

Continue reading

Pixium Vision sélectionné pour participer au programme Next French Healthcare organisé par Business France et BPI France, intensifiant ainsi sa présence aux États-Unis

Pixium Vision sélectionné pour participer au programme Next French Healthcare organisé par Business France et Bpifrance, intensifiant ainsi sa présence aux États-UnisParis, le 19 juin 2020 – 07h30 CET – Pixium Vision (Euronext Growth Paris – FR0011950641), une société de bioélectronique qui développe des systèmes de vision bionique innovants pour permettre aux patients qui ont perdu la vue de vivre de manière plus autonome, annonce aujourd’hui faire partie des 13 healthtech françaises les plus innovantes sélectionnées pour participer au mois d’octobre prochain, à un roadshow aux Etats-Unis organisé par Business France et Bpifrance.Pixium Vision présentera le plan de développement clinique et commercial du Système Prima à de potentiels investisseurs américains sur la base de récentes données cliniques sur 18 mois...

Continue reading

World’s First Gaming Browser, Opera GX, Adds Built-in Discord Support and Other Features in Major Birthday Release

OSLO, Norway, June 19, 2020 (GLOBE NEWSWIRE) — Opera GX, the world’s first gaming browser, is introducing new features including Discord support and a Hot tabs killer. It can also force brightly-designed pages to become dark to stop that nighttime glare.–       Opera believes that more than one billion PC gamers around the world deserve a browsing experience tailored to their needs–       Opera GX remains the only web browser made specifically for people who love and play video games and experienced a 121% growth in monthly users since end of 2019   With 1.3 billion PC gamers around the world and the gaming industry surpassing the movie and music business in revenue, Opera GX [NASDAQ: OPRA] remains the only PC browser designed with gamers’ needs in mind. The browser has many useful features including Twitch integration,...

Continue reading

uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first two patients in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease have been treated. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States, with now one patient treated with AMT-130, and one patient who received the imitation surgery.“For years, uniQure has had an unwavering commitment to advance this first-in-human AAV gene therapy for Huntington’s disease into clinical testing, and this moment marks an important milestone for our company now that we have two AAV gene therapy candidates in clinical development,” said Matt...

Continue reading

D. Gesevicius as CEO of Panevezio statybos trestas AB Will be Replaced by E. Urbonas

Dalius Gesevicius, Managing Director of Panevezio statybos trestas AB, leaves the company by the mutual decision. Based on the decision taken by the Board, from June 23rd the position of Managing Director will be taken over by Egidijus Urbonas who has been managing the companies of the PST Group – Metalo meistrai UAB and Hustal UAB.More information:Managing DirectorDalius GeseviciusTel.: (+370 45) 505 503

Continue reading

PST vadovo pareigose D.Gesevičių keičia E.Urbonas

AB „Panevėžio statybos trestas“ (PST) direktorius Dalius Gesevičius abipusiu susitarimu palieka Bendrovę. Valdybos sprendimu, nuo birželio 23 d. generalinio direktoriaus pareigas perims Egidijus Urbonas, iki šiol vadovavęs PST grupės įmonėms UAB „Metalo meistrai“ ir UAB „Hustal“.Daugiau informacijos:Generalinis direktoriusDalius GesevičiusTel.: (8-45) 505 503

Continue reading

Cryptologic Announces Conversion of Outstanding Debentures

TORONTO, June 19, 2020 (GLOBE NEWSWIRE) — Cryptologic Inc. (“Cryptologic” or the “Company”) (CSE:CRY) today announces the Company is providing notice to holders of its 8% extendible convertible unsecured debentures that the Company is completing the conversion (the “Conversion”) of all outstanding debentures into common shares (the “Common Shares”) of the Company at a conversion price of $1.00 (the “Conversion Price”), and that Cryptologic will provide for the payment of accrued interest to the date of Conversion by issuing Common Shares at a price equal to the accrued interest divided by the Conversion Price. The Company currently has 12,719,162 Common Shares issued and outstanding. An aggregate of 35,880,000 Common Shares will be issued as a result of the Conversion and payment of accrued interest in Common Shares.At a special...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.